|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.08.26 - 13:03
|
Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency (GlobeNewswire EN)
|
|
|
BARCELONA, Spain, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the completion of the clinical portion of SPARTA (Study of ProlAstin-C Randomized Therapy with Alpha-1 augmentation; NCT01983241), its phase 3 outcomes study evaluating the clinical efficacy and safety of two dose regimens of Prolastin®-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema associated with alpha-1 antitrypsin deficiency (AATD), also known as alpha-1....
|
|
|
|
|
|
|
29.07.26 - 14:33
|
FOXO TECHNOLOGIES INC.′S SUBSIDIARY VECTOR BIOSOURCE, INC. ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE FOUR BLOOD COLLECTION CENTERS FROM GRIFOLS BIO SUPPLIES, INC. (GlobeNewswire EN)
|
|
|
WEST PALM BEACH, FL, July 29, 2026 (GLOBE NEWSWIRE) -- FOXO Technologies Inc.'s (OTC: FOXOD/FOXO) ( “FOXO”) subsidiary, Vector BioSource, Inc. (“Vector”) today announced that it has entered into a definitive agreement to acquire four U.S.-based blood collection centers (the “Agreement”) from Grifols Bio Supplies, Inc., a U.S.-based subsidiary of Grifols S.A. The acquisition is intended to provide a proprietary source of bio-products to sell to Vector's customers to augment its existing sourcing model. Furthermore, the new FDA licensure that Vector expects to be required is anticipated to further expand Vector's accessible market....
|
|
|
|
|
28.07.26 - 20:00
|
Grifols H1 Profit Rises 29%; Backs FY26 Outlook (AFX)
|
|
|
MADRID (dpa-AFX) - Grifols S.A. (GRFS) on Tuesday reported higher profit for the first half of 2026, supported by growth in its Biopharma business. The company also reaffirmed its full-year guidan......
|
|
|
|
|
16.07.26 - 14:03
|
Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins (GlobeNewswire EN)
|
|
|
BARCELONA, Spain, July 16, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced that the first patients have been dosed in two separate Phase 3 trials aiming to expand the U.S. labels for its signature immunoglobulin therapeutics, GAMUNEX®-C, an intravenous immunoglobulin (IVIg), and XEMBIFY®, its subcutaneous immunoglobulin (SCIg)....
|
|
|
15.06.26 - 14:03
|
Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S. (GlobeNewswire EN)
|
|
|
BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the U.S. launch of its new fibrinogen concentrate. Approved by the U.S. Food and Drug Administration in December for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency (CFD), including hypo- or afibrinogenemia, FESILTY™ (fibrinogen, human-chmt) is now available in the U.S. FESILTY is not indicated for dysfibrinogenemia....
|
|
|
05.06.26 - 22:18
|
Grifols Supports AlphaDetect to Accelerate Detection of Alpha-1 (PR Newswire)
|
|
|
The sponsorship will help expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease. DURHAM, N.C., June 5, 2026 /PRNewswire/ -- AlphaDetect, the nonprofit detection organization powered and funded by the......
|
|
|
|
|
|
|
07.05.26 - 19:24
|
Grifols Q1 Profit Rises (AFX)
|
|
|
MADRID (dpa-AFX) - Plasma-derived medicines company Grifols S.A. (GRFS) on Thursday reported higher first-quarter profit and revenue, driven by continued strong demand for immunoglobulin therapies......
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
